Bibliotecas PUC-SP - Busca Integrada

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

per Maarten J. Deenen, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens
Publicat a Therapeutic Advances in Medical Oncology (2013-01-01)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis

per Anke E. Kip, Monique Wasunna, Fabiana Alves, Jan H. M. Schellens, Jan H. M. Schellens, Jos H. Beijnen, Jos H. Beijnen, Jos H. Beijnen, Ahmed M. Musa, Eltahir A. G. Khalil, Thomas P. C. Dorlo
Publicat a Frontiers in Cellular and Infection Microbiology (2018-06-01)

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar

per Emilia Sawicki, Michel J. Hillebrand, Hilde Rosing, Jan H.M. Schellens, Bastiaan Nuijen, Jos H. Beijnen
Publicat a Journal of Pharmaceutical Analysis (2016-08-01)

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer

per Marie-Rose B.S. Crombag, Markus Joerger, Beat Thürlimann, Jan H.M. Schellens, Jos H. Beijnen, Alwin D.R. Huitema
Publicat a Cancers (2016-01-01)

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy

per J. G. Coen van Hasselt, Karel Allegaert, Kristel van Calsteren, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema
Publicat 2014-01-01

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”

per J. G. Coen van Hasselt, Karel Allegaert, Kristel van Calsteren, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema
Publicat 2015-01-01

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple <i>DPYD</i> Variants

per Carin A. T. C. Lunenburg, Linda M. Henricks, André B. P. van Kuilenburg, Ron H. J. Mathijssen, Jan H. M. Schellens, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J. Swen
Publicat a Genes (2018-11-01)

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

per Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema
Publicat a CPT: Pharmacometrics & Systems Pharmacology (2019-12-01)

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort

per Aurelia H. M. deVries Schultink, Marie‐Rose B. S. Crombag, Erik vanWerkhoven, Hans‐Martin Otten, Andre M. Bergman, Jan H. M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen
Publicat a Cancer Medicine (2019-04-01)

Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk

per Judith Y.M.N. Engwegen, Annekatrien C.T.M. Depla, Annemieke Cats, Henriëtte Tuynman, Henk A. van Heukelem, Pleun Snel, Wouter Meuleman, Lodewyk Wessels, Jan H.M. Schellens, Jos H. Beijnen
Publicat a Biomarker Insights (2008-01-01)

No relation between docetaxel administration route and high‐grade diarrhea incidence

per Jeroen J. M. A. Hendrikx, Frederik E. Stuurman, Ji‐Ying Song, Vincent A. deWeger, Jurjen S. Lagas, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel, Jan H. M. Schellens, Serena Marchetti
Publicat a Pharmacology Research & Perspectives (2020-08-01)

Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk

per Judith Y.M.N. Engwegen, Annekatrien C.T.M. Depla, Marianne E. Smits, Annemieke Cats, Henriëtte Tuynman, Henk A. Van Heukelem, Pleun Snel, Wouter Meuleman, Lodewyk F. Wessels, Jan H.M. Schellens, Jos H. Beijnen
Publicat a Biomarker Insights (2008-01-01)

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors

per Daphne W. M. Voogd, Merel J. J. Lucassen, Ruud van der Noll, Sybrand W. J. Zielhuis, David Boss, Jos H. Beijnen, Hilde Rosing, Matthijs Tibben, Alwin D. R. Huitema, Jan H. M. Schellens, Neeltje Steeghs
Publicat a Oncology and Therapy (2025-05-01)

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine

per Femke M. de Man, G.D. Marijn Veerman, Esther Oomen-de Hoop, Maarten J. Deenen, Didier Meulendijks, Caroline M.P.W. Mandigers, Marcel Soesan, Jan H.M. Schellens, Esther van Meerten, Teun van Gelder, Ron H.J. Mathijssen
Publicat a Therapeutic Advances in Medical Oncology (2019-04-01)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

per Hans Gelderblom, Patrick M Forde, Aung Naing, Matthew Taylor, Jennifer Mataraza, Marcus O Butler, Todd M Bauer, Justin F Gainor, Chia-Chi Lin, Sunil Sharma, Maria Ochoa de Olza, Andrea Varga, Jan H M Schellens, Hongqian Wu, Haiying Sun, Antonio P Silva, Jason Faris, Scott Cameron
Publicat a Journal for ImmunoTherapy of Cancer (2020-05-01)

A phosphotyrosine switch regulates organic cation transporters

per Jason A. Sprowl, Su Sien Ong, Alice A. Gibson, Shuiying Hu, Guoqing Du, Wenwei Lin, Lie Li, Shashank Bharill, Rachel A. Ness, Adrian Stecula, Steven M. Offer, Robert B. Diasio, Anne T. Nies, Matthias Schwab, Guido Cavaletti, Eberhard Schlatter, Giuliano Ciarimboli, Jan H. M. Schellens, Ehud Y. Isacoff, Andrej Sali, Taosheng Chen, Sharyn D. Baker, Alex Sparreboom, Navjotsingh Pabla
Publicat a Nature Communications (2016-03-01)

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

per Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore
Publicat a Journal for ImmunoTherapy of Cancer (2023-03-01)

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

per Jonathan E. Knikman, Qinglian Zhai, Carin A. T. C. Lunenburg, Linda M. Henricks, Stefan Böhringer, Maaike van der Lee, Femke M. de Man, Steven M. Offer, Shikshya Shrestha, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentjé, Alexander L. T. Imholz, Frank J. F. Jeurissen, Johanna E. A. Portielje, Rob L. H. Jansen, Paul Hamberg, Helga J. Droogendijk, Miriam Koopman, Peter Nieboer, Marlène H. W. van de Poel, Caroline M. P. W. Mandigers, Ron H. N. van Schaik, Hans Gelderblom, Ron H. J. Mathijssen, Jan H. M. Schellens, Annemieke Cats, Henk-Jan Guchelaar, Jesse J. Swen
Publicat a Genome Medicine (2024-08-01)